Upstream Bio, Inc.
UPBNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | |
|---|---|---|---|
| Revenue | $2.9M | $2.4M | $2.4M |
| Operating income | −$160.4M | −$77.8M | −$40.1M |
| Net income | −$143.4M | −$62.8M | −$20.5M |
| Total assets | $353.8M | $481.7M | $117.2M |
| Total liabilities | $14.0M | $11.9M | $9.4M |
| Equity | $339.8M | $469.9M | −$123.1M |
| EPS (diluted) | $-2.66 | $-5.58 | $-12.95 |
| Shares out. | 53.6M | 53.6M | 3.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −5618.8%
- Net margin
- −5026.0%
- Return on equity
- −42.2%
- Return on assets
- −40.5%
- Return on capital (ROCE)
- −47.1%
- Liabilities / assets
- 4.0%
- Debt / equity
- 0.04×
- Book value / share
- $6.33
- Revenue growth (YoY)
- 20.4%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 25.63safe
- Accruals / assets
- −2.9%clean
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 warning● 4 good- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2Active Not Recruitingreadout ~2027-09A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
- Phase 2Recruitingreadout ~2028-04A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 3.4M | 6.7 | +5.4% |
| Apr 30, 2026 | 3.2M | 5.7 | +6.6% |
| Apr 15, 2026 | 3.0M | 5.2 | -12.0% |
| Mar 31, 2026 | 3.4M | 3.5 | -27.7% |
| Mar 13, 2026 | 4.8M | 4.4 | +16.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 13, 2026
- Entered a material agreementMar 26, 2026
- Results of operationsMar 26, 2026
- Results of operations · Regulation FD disclosureFeb 11, 2026
- Regulation FD disclosure · Other material eventFeb 11, 2026
- Results of operationsNov 5, 2025
- Regulation FD disclosure · Other material eventSep 2, 2025
- Results of operationsAug 6, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.